Sutro Biopharma, Inc. STRO 深 沪
等待开盘 04-02 09:30:00 美东时间
24.87
-0.040
-0.16%
华盛通- 最 高26.345
- 今 开25.19
- 成交量 11.13万股
- 最 低 24.57
- 昨 收 24.91
- 总市值 4.12亿
- 52周最高 26.54
- 市盈率 静 --
- 换手率 0.67%
- 52周最低 5.231
- 委 比 33.33%
- 总股本 1656.72万
- 历史最高 283.00
- 量 比 0.59
- 振 幅 7.13%
- 历史最低 5.231
- 每 手 1
- 风险率 4.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
03-26 11:41
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
This Ralph Lauren Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts upgraded STRO, JKS, AJG, ECL, RL stocks. See analysts' ratings and price targets on Benzinga's analyst ratings page.
03-24 21:27
HC Wainwright & Co. Upgrades Sutro Biopharma to Buy, Raises Price Target to $28
HC Wainwright & Co. analyst Andres Y. Maldonado upgrades Sutro Biopharma (NASDAQ:STRO) from Neutral to Buy and raises the price target from $10 to $28.
03-24 18:17
Sutro Biopharma Q4 EPS $(5.29) Misses $(4.35) Estimate, Sales $11.647M Beat $8.341M Estimate
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(5.29) per share which missed the analyst consensus estimate of $(4.35) by 21.58 percent. This is a 40.56 percent increase over losses of $(8.90) per share from
03-24 04:13
Sutro Biopharma shares are trading higher after the company announced pricing of an underwritten offering of 7.76 million shares at $13.98 per share.
Sutro Biopharma shares are trading higher after the company announced pricing o...
02-11 01:28
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Citizens Upgrades Sutro Biopharma to Market Outperform, Announces $23 Price Target
Citizens analyst Reni Benjamin upgrades Sutro Biopharma (NASDAQ:STRO) from Market Perform to Market Outperform and announces $23 price target.
01-20 18:25
